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transition rates. Disease state costs were obtained from 2013 UK data, with discount-
ing set to 3.5%. Weekly costs were: DCV= £2,043.15, SOF= £2,915.24 and RBV= £66.95. 
Clinical inputs were obtained from a matching-adjusted indirect comparison 
(adjusts for baseline differences between trials) of ALLY-3 and VALENCE: SVRs for 
DCV+SOF and SOF+RBV, respectively, were 96.4% and 94.3% for treatment-naïve, 
83.2% and 78.6% for treatment-experienced and 88.8% and 85.2% for interferon-
ineligible intolerant patients). RESULTS: In all comparisons, DCV+SOF was pre-
dicted to be associated with reduced total costs and improved QoL versus SOF+RBV: 
Treatment naïve: DCV+SOF expected to be associated with cost savings of £12,903 
and QALY gains of 0.13. Treatment-experienced: DCV+SOF expected to be associated 
with cost savings of £13,701 and QALY gains of 0.24. Interferon-ineligible/intolerant: 
DCV+SOF expected to be associated with cost savings of £13,382 and QALY gains 
of 0.2. Versus no treatment, DCV+SOF is expected to be cost-effective (total cost 
£31,875 and QALY gain of 4.12; ICER of £7,743) for interferon-ineligible/intolerant 
patients. CONCLUSIONS: 12 weeks of DCV+SOF appears a cost-effective treatment 
option for patients with HCV genotype 3 in all modelled scenarios. When compared 
to 24 weeks of SOF+RBV, DCV+SOF was predicted to be dominant.
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Cost ImPlICatIoNs of tedIzolId use IN aCute BaCterIal skIN aNd 
skIN struCture INfeCtIoN (aBsssI) for HosPItals aNd maNaged Care 
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OBJECTIVES: A 6-day, once-daily course of tedizolid, a novel oxazolidinone antibacte-
rial, demonstrated non-inferior efficacy and comparable safety to a 10-day course of 
twice-daily linezolid in ABSSSI. We examined the economic impact of tedizolid as an 
alternative to linezolid on hospitals and MCOs. METHODS: Cost implications of tedi-
zolid versus linezolid use were examined via cost-minimization analysis. Treatment 
durations for tedizolid and linezolid were modeled at 6 and 10 days, respectively, 
consistent with approved drug labels. ABSSSI patients were assumed to initiate par-
enteral (IV) therapy in the hospital and switch to oral formulations upon discharge to 
complete any remaining days of therapy (DOT). Inpatient linezolid DOT were derived 
from 2008-2012 the Truven MarketScan® claims and linked Hospital Drug Database 
(HDD). Adult patients with a primary or secondary diagnosis consistent with ABSSSI 
and ≥ 90 days continuous eligibility prior to admission were included in the analysis. 
Patients with ≤ 6 inpatient linezolid DOT were modeled as receiving the same inpa-
tient DOT with tedizolid; patients with 7-10 inpatient linezolid DOT were modeled 
as completing a 6-day course of tedizolid in hospital. Daily drug costs were based on 
lowest, published wholesale average cost and included preparation/administration 
costs. RESULTS: Of 3,329 ABSSSI hospitalizations identified in the HDD, 261 (7.1%) 
were treated with linezolid an average of 4.2 days; outpatient linezolid DOT were 
estimated at 5.8 days. Inpatient and outpatient tedizolid DOT were estimated at 3.8 
and 2.2 days, respectively. Average total drug costs for a 10-day course of linezolid 
were calculated as $2,816 per patient ($1,050 inpatient, $1,766 outpatient), compared 
to $1,562 ($910 inpatient, $652 outpatient) for a 6-day course of tedizolid. Inpatient 
and outpatient cost savings were maintained at linezolid daily costs at or above $213 
and $111, respectively. CONCLUSIONS: Tedizolid is expected to reduce antibacterial 
treatment costs, with the greatest impact occurring in the outpatient setting.
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HIgH-dose INaCtIvated INflueNza vaCCINe Is assoCIated WItH 
Cost savINgs aNd Better outComes ComPared to staNdard-dose 
INaCtIvated INflueNza vaCCINe IN seNIors
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OBJECTIVES: Adults ≥ 65 years account for most seasonal influenza-related hos-
pitalizations and deaths. A recent 32,000-participant, head-to-head RCT (FIM12, 
NCT01427309) demonstrated that a high-dose influenza vaccine (HD) was 24.2% more 
efficacious than a standard-dose influenza vaccine (SD) in adults ≥ 65 years. A cost-
utility analysis (CUA) of HD vs. SD in FIM12 participants was performed. METHODS: 
Health-care resource utilization data collected in the FIM12 study included: medica-
tions, non-routine medical and emergency room visits, and hospitalizations. Utilized 
resources were summarized across vaccine arms and unit costs were applied, using 
standard US cost sources, to each resource item (including vaccines; HD $31.82; SD 
$12.04) to estimate the mean total direct medical and societal costs associated with 
each vaccine. Adverse event data from the trial were mapped to quality of life data 
from the literature to estimate the effectiveness of both vaccines. The time horizon 
was one year’s influenza season for costs and a lifetime for quality-adjusted life 
years (QALYs). RESULTS: The average per-participant direct medical costs (including 
influenza vaccine cost) and societal costs were $116 and $128 lower in the HD arm. 
Hospitalizations represented over 95% of the total cost and were less frequent in the 
HD arm (7.7% of HD participants reported ≥ 1 hospitalization versus 8.4% in SD arm) 
and average length of stay (LOS) across all participants was shorter in the HD arm (0.49 
days vs 0.56 days). HD was associated with 0.0004 more QALYs per participant and, 
due to cost savings, dominated SD in the CUA. CONCLUSIONS: Despite the higher 
price of HD vs. SD, the total direct medical and societal costs were over $100 lower per 
vaccinee in those who received HD. This was driven by a reduction in the number of 
hospitalizations and in the LOS for those hospitalized. HD dominated SD in the CUA.
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OBJECTIVES: Pneumococcal infections are a public health problem in older adults. 
In Chile there are two vaccines at this time, PPSV23 and PCV13. The objective of 
QALYs outcome used utility data from other studies, of which only one used utilities 
generated in Chinese population. 29% of those with composite outcomes DALYs 
and QALYs included cases, deaths and life years at time. 47% considered indirect 
cost due to causes such as sick leave and loss of productivity in addition to direct 
cost for the analysis. All but one studies included sensitivity analysis, but 53% did 
not conduct probability sensitivity analysis to see the joint effect of uncertainties 
around multiple parameters. Six (35%) were post hoc studies assessing the cost-
effectiveness of current vaccination compared with the non-vaccination alterna-
tive. All studies except one on 7-valent pneumococcal conjugate vaccine showed 
cost-effectiveness for the vaccinations. CONCLUSIONS: Major methodological flaws 
and reporting problems exist in economic evaluations for vaccines in China. Local 
guidelines for good practice and reporting are demanded in addition to institutional 
mechanisms and education for improve the overall quality of economic evaluation 
work for immunization programs in China.
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Cost- effeCtIveNess aNalysIs of NevIraPINe vs. rItoNavIr-Boosted 
loPINavIr IN HIv-INfeCted CHIldreN WItH PerIPartum NevIraPINe 
exPosure, IN resourCe-CoNstraINed areas from a Payer’s PersPeCtIve
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OBJECTIVES: A regimen including nevirapine (NVP) is often the predominant 
antiretroviral therapy (ART) available for children infected with human immuno-
deficiency virus (HIV) in Africa, because it is inexpensive, stable at high tempera-
tures, and used as a single dose for the prevention of mother-to-child transmission 
(PMTCT) of HIV. Despite the benefits of NVP, challenges exist from the effect of NVP 
resistance in children who become infected with HIV regardless of prophylaxis. 
As a result of these concerns, ritonavir-boosted lopinavir (LPV/r) based regimens, 
although more expensive, are preferred by some clinicians over the less costly NVP-
based regimens. We therefore evaluated the cost-effectiveness of NVP-based regi-
mens to LPV/r-based regimens as a first-line treatment option for children with HIV 
after virologic suppression. METHODS: A Markov Model was designed to compare 
the cost-effectiveness of NVP-based regimens to LPV/r-based regimens for HIV-
infected children with three HIV transition states, CD4% > 15, CD4% < 15, and death. 
The clinical and costs data were collected from published studies of ART for children 
in South Africa and based on time horizons of one year and lifetime. RESULTS: The 
resultant Incremental Cost Effectiveness Ratio (ICER) from this study demonstrates 
that the NVP based strategy is cost effective, with the incremental cost and the 
incremental QALY of the time horizon of one-year and lifetime of, $690.15/0.92QALY 
and $22,578.25/30.27QALY respectively. CONCLUSIONS: For HIV infected children 
with a history of exposure to single dose NVP (sdNVP) from PMTCT prophylaxis, it 
is cost-effective to switch to NVP-based regimens as a first-line treatment option 
after virologic suppression with LPV/r based HAART.
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Cost-effeCtIveNess aNalysIs of vaCCINatIoN agaINst raBIes IN dogs 
IN ColomBIa
Castillo-Rodríguez L., Castañeda-Orjuela C.A., De la Hoz-Restrepo F.
Instituto Nacional de Salud, Bogotá, Colombia
OBJECTIVES: To estimate the cost-effectiveness of rabies vaccination program in 
dogs to prevent human rabies in Colombia. METHODS: A Markov model with daily 
cycles was designed to simulate the dynamics of the transmission of rabies in 
the dog population of Colombia. A Literature review for identifying transmission 
parameters within dog population and transmission to humans was carried out. The 
model considered two alternatives: No vaccination and dog vaccination (comparing 
different vaccination coverage). The burden of disease in human population, during 
one year, in terms of years of life lost (YLL) was estimate and program and care costs 
were collected from a third payer perspective. Incremental cost effectiveness ratio 
(ICER) of vaccination versus no vaccination was estimated. All cost were adjusted 
to 2013 US dollars. RESULTS: With no vaccination 58,591 of dog rabies cases were 
estimated whit 5 human cases and 338 YLL. With vaccination at a 68% coverage and 
75% of vaccine effectiveness, 28,664 dog cases and 2 human cases were estimated. 
The vaccination costs were US $ 777,331.76; administration costs of US $ 1,426,463.00 
and wastage costs were estimated at US $ 77,733.18; for a total program cost of US 
$ 220,379,48. The variation in vaccination coverage, introduced significant changes, 
the most significant change is reflected in the costs to present a case of human 
rabies; with the current coverage is US $ 10,394.87 to $ 6,933.36 USD (90% coverage). 
The incremental cost effectiveness ratio (ICER) would be between 654 and 704 per 
additional year of life gained. CONCLUSIONS: Increase vaccination coverage in dogs 
to decrease the incidence of human rabies is a cost-effective strategy in Colombia.
PIN73
estImatINg tHe Cost-effeCtIveNess of 12 Weeks of treatmeNt WItH 
daClatasvIr+sofosBuvIr IN PatIeNts CHroNICally INfeCted WItH HCv 
geNotyPe 3
McEwan P.1, Ward T.1, Webster S.1, Kalsekar A.2, Brenner M.3, Yuan Y.4
1Health Economics and Outcomes Research Ltd, Monmouth, UK, 2Bristol-Myers Squibb, Princeton, 
NJ, USA, 3Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK, 4Bristol-Myers Squibb 
Pharmaceuticals Ltd, Princeton, NJ, USA
OBJECTIVES: Chronic infection with hepatitis C virus (HCV) genotype 3 is associated 
with faster disease progression and is considered difficult to treat. The objective 
of this investigation was to compare the cost-effectiveness of two new all-oral, 
interferon-free treatment regimens: daclatasvir plus sofosbuvir (DCV+SOF) and 
sofosbuvir plus ribavirin (SOF+RBV). Historically, patients ineligible for/intoler-
ant to interferon had no available treatment option; therefore, a comparison to no 
treatment was also made in these patients. METHODS: A published Markov model 
(MONARCH) was used to estimate the cost-effectiveness of treatment regimens 
over a lifetime horizon. Patients were evenly distributed across fibrosis stages F0–F4 
upon treatment initiation. Patients progress through disease stages using published 
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cope with forgetfulness, specifically employing strategies to overcome busyness 
in schedules, being away from home and tiredness.
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adHereNCe amoNg HIv PatIeNts IN etHIoPIa
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OBJECTIVES: The study aimed to assess the pattern of traditional medicine(TM) 
use and its impact on antiretroviral therapy (ART) adherence among HIV patients 
in Addis Ababa, Ethiopia. METHODS: A cross-sectional study was conducted 
among HIV patients on ART in Addis Ababa public ART clinics, from September 
to October 2013. The study population consisted of 845 HIV patients who were on 
ART at least for six months, selected by systematic sampling technique from nine 
randomly selected clinics. Data were collected by trained health professionals 
through face-to-face interview of patients, using pre-tested questionnaire. Data 
were entered to Epi-info version 7 and analyzed by SPSS version 16. Logistic regres-
sion was used to assess the impact of TM use on ART adherence. RESULTS: Eight 
hundred forty-five patients were included in the study, 572 (67.7%) of which were 
females. A third (33.2%) of the patients were TM and ART concomitant users. Most 
frequently used TM were Alium sativum (34%) and Ocimum lamifolia (28%); mainly 
for the purpose of managing HIV/AIDS related symptoms (61.2%). Most (68.7%) 
of the patients were using TM without consulting health professionals. Factors 
independently associated with concomitant TM and ART use were perceived qual-
ity of service in ART clinics (poor vs good, AOR 2.35; 95% CI 1.78-3.44), number of 
ART side effects reported (≥ 3 vs ≤ 1, AOR 2.61 95%CI 1.53-5.47) and self-perceived 
health status (poor vs good, AOR 2.14; 95% CI 1.62-6.31). Concomitant TM and ART 
use had statistically significant association with poor ART adherence (AOR 3.15; 
95% CI 2.32-6.32). CONCLUSIONS: The study revealed that many patients used TM 
concomitant to ART. Since TM use among the patients was found to impact their 
ART adherence and because of the possibility for interaction, patients should be 
advised to consult their health care providers when they need to take TM while 
on ART.
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use of HealtH BelIef model to uNderstaNd kNoWledge, attItudes 
aNd BeHavIors of PeoPle toWards tHe eBola outBreak
Vadhariya A., Sansgiry S.S.
University of Houston, Houston, TX, USA
OBJECTIVES: The outbreak of Ebola in 2014 has been the largest in history, affecting 
multiple countries in West Africa and cases were diagnosed within the United States 
as well. This study uses the framework of the Health Belief Model and aims to under-
stand the perceptions of a cohort of individuals in Houston, Texas towards this out-
break, measured as the likelihood of performing preventive behaviors. METHODS: 
This is a prospective, cross sectional study design with an anonymous, self-admin-
istered survey based on the constructs of the Health Belief Model. Individuals aged 
18 or older were requested for their participation by convenience sampling at public 
places in Houston, Texas between 4th November and 28th December 2014. The 
variables measured were perceived susceptibility, perceived severity, perceived 
threat, knowledge about Ebola, self-efficacy and existing health belief. For statisti-
cal analysis the Health Belief Model based statements in the survey were grouped 
as per domain, the scores were summed up to give the variable values, which were 
tested in a multiple regression model. RESULTS: A total of 283 participants aged 
18 to 74 (Mean: 34.5±12.7, 54.8% male) completed the survey. Of the Health Belief 
Model constructs tested for, perceived susceptibility (p= 0.0366), perceived threat 
(p< 0.0001), educational level (p= 0.0470), actively following the news (p= 0.0015) 
and existing health belief (p= 0.0003) were predictors of the likelihood to perform 
preventive health behaviors. CONCLUSIONS: The Health Belief Model adequately 
predicted public perception regarding their belief about the threat of the disease 
and susceptibility towards the disease. Educating the public about the actual risks 
of Ebola in United States through various media can elicit appropriate behavior in 
any future cases of outbreak within the United States.
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OBJECTIVES: We sought to identify pneumonia knowledge among participants in the 
Pharmacist’s Pneumonia Prevention Project (PPPP), a community-based education 
and vaccination program administered to older Philadelphians in 2014. METHODS: 
Participants were aged 50+, cognitively intact, English speaking and recruited from 
senior centers and churches with a predominantly black population in Philadelphia. 
This analysis reports baseline data which were collected prior to delivery of PPPP. 
Knowledge and awareness of pneumonia was assessed with a 22-item question-
naire encompassing the following domains: susceptibility to infection, symptoms 
of disease, severity of illness, and vaccination with an emphasis on vaccine efficacy, 
safety, and eligibility. RESULTS: 203 individuals were enrolled, of whom 75% were 
female and 80% were black, with a mean age of 74(SD 9) years. Additionally, 148 
(73%) participants had at least a high school education. Of the 203 participants, 97 
(48%) described pneumonia in their own words, but only 33 of these (34%) correctly 
described it as an infection in the lungs. When asked about the best way to prevent 
pneumonia, 47% of participants reported answers other than vaccination. Compared 
to women, more men were unaware of the individuals who were at risk of getting 
pneumonia. Specifically, 81% of men did not think that the very young were at risk of 
getting the disease (vs. 56% of women; p= 0.032). Additionally, 76% of men were una-
ware that patients with a low immune system were at risk for pneumonia (vs. 39% of 
women; p= 0.002). CONCLUSIONS: Findings revealed critical knowledge gaps about 
pneumonia, underscoring the need for educational approaches which resonate with 
this study is to determine the cost-effectiveness of a PCV13 vaccination program 
versus a PPSV23 program in high risk adults 18 years old and over with a coverage 
of 100% and in healthy adults 65 years old with a coverage of 90%, in the Chilean 
Health System. METHODS: A cost/utility study was performed using a Markov 
model (population data for a time horizon of 10 years). Utilities and epidemio-
logical data like incidence, mortality, and consequences of pneumococcal disease 
were obtained from Chilean, Latin American and International published literature. 
Vaccine’s efficacies were taken from literature for PPSV23 and from the Community-
Acquired Pneumonia Immunization Trial in Adults (CAPITA) for PCV13. Direct and 
indirect costs were considered and were obtained from FONASA, the Chilean Public 
Health Insurance. Vaccine’s costs and quality-adjusted life of years (QALYs) were 
determined and compared. RESULTS: With a PCV13 vaccination program, 107 cases 
of bacteremia, 13 of meningitis, 6,706 of inpatient pneumonia, 4,509 of outpatient 
pneumonia and 1,189 deaths were avoided compared with PPSV23 program. The 
total cost over the 10 year period studied, and for the total population of 12,773,697 
people, was $1,994,404 for PCV13 and $2,026,510 for PPSV23. For PCV13, QALYs 
were 11,484,554 and for PPSV23, QALYs were 11,479,124, thus the Incremental Cost/
Effectiveness Ratio (ICER) was dominant for PCV13, and these results do not vary 
with sensitivity analysis on high impact variables. CONCLUSIONS: A PCV13 vac-
cination program is dominant over a PPSV23 program, and a population program 
with PCV13 would save public health expenses and reduce morbidity, mortality 
and disability in Chilean adults over 18 years old. These results appear to be robust 
under a variety of sensitivity analysis.
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PredICtINg HumaN ImmuNodefICIeNCy vIrus veteraNs’ adHereNCe to 
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OBJECTIVES: Human immunodeficiency virus (HIV) treatment guidelines recom-
mend target adherence levels of 95% and suggest that treatment be postponed in 
patients at risk of poor adherence. Little objective guidance is provided to clini-
cians for identifying such patients. We applied an optimal data analysis (ODA) 
paradigm to create predictive models for adherence in a national cohort of United 
States veterans using electronic medical records (EMRs) by maximizing predic-
tive accuracy. METHODS: Quarterly adherence to antiretroviral agents was calcu-
lated as the proportion of days covered (PDC) with 3 or more antiretroviral agents 
from 2 or more drug classes. A hierarchical decision tree was built to predict 
patient adherence at different adherence thresholds of 75%, 80%, 85%, 90% and 
95%. The attribute variables included demographics, comorbidities, and disease 
characteristics. Three rules were applied to pick the predictors: 1) at each deci-
sion point, the attribute with the lowest Fisher’s exact p-value was selected; 2) 
leave-one-out jackknife analysis was performed to select a stable attribute; and 
3) dividing a branch of decision tree was stopped if the branch had less than 
15 patients. RESULTS: 3864 HIV patients newly initiated highly active antiret-
roviral therapy in 1998-2006. The mean age of the cohort was 56.3±9.4 year old 
and 98.4% were males. The mean (95% CI) PDC in quarter 1 was 20.9% (41.6-45.0) 
and reached a maximum of 43.3% (20.2-21.7) in quarter 26. The ODA models for 
different thresholds predicted adherence with a C-statistic of 0.58-0.63, a range 
of accuracy defined as no discrimination to poor discrimination. Patients who 
were most non-adherent were those who were < 60 years old, black, treated with 
protease inhibitors and drug abuser. CONCLUSIONS: Using discrete data in the 
EMRs, it is difficult to predict patients at risk of poor adherence. Future work 
should include more complex predictors such as patient adherence to other 
therapies.
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OBJECTIVES: The objectives of this study were to describe and compare adherence 
rates and to determine what factors are related to adherence to therapy among 
patients living with HIV/AIDS receiving Highly Active Antiretroviral Therapy 
(HAART) in a treatment center in Lagos, Nigeria. METHODS: Patients in the study 
were living with HIV/AIDS, 18 years or older, receiving HAART, and had visited 
the clinic between June and July 2012. Adherence was measured using two self-
reported measures: number of doses taken over the past two weeks/number of 
doses provided over the past two weeks and the valid and reliable Morisky scale. 
Barriers, satisfaction with therapy, and sociodemographic and clinical variables 
served as independent variables. Data were collected via self-administered sur-
veys. Descriptive statistics, Pearson’s correlation, McNemar’s test, Pearson’s chi-
square test, analysis of variance, and logistic regression were used to address study 
objectives. RESULTS: The majority of the study sample (N= 361) were between 18 
and 40 (64.9%), female (58.3%), married (64.8%), working (83.8%), and on HAART for 
at least one year (82.0%) while a plurality of the sample had a college education 
(46.5%). Most of the patients (79.5%) reported 100% adherence using two-week self-
recall and 49.6% using the Morisky scale. Both methods used to measure adher-
ence were significantly correlated (rho= 0.476; p< 0.001). The significant (p< 0.01) 
barriers to adherence between those 100% and < 100% adherent were forgetfulness, 
running out of medication, alcohol use, and medication side effects. Multivariate 
logistic regression analysis showed that for every unit increase in the number of 
barriers, patients were 60.8% less likely to be 100% adherent (p< 0.001, OR= 0.392, 
95% CI= 0.295-0.523). CONCLUSIONS: Interventions should target helping patients 
